


Brainsway Deep TMS

Remission Accomplished



- ▶ A cutting edge non-medication non-invasive treatment for depression
- ▶ Therapeutic benefit across a wide range of treatment-resistance¹

Treat to remission



In the United States, approximately **1 in 6** individuals will suffer from major depressive disorder during their lifetime. Nearly 15 million Americans experience a major depressive episode each year.²

The ultimate therapeutic goal of any depression treatment is remission.

The STAR*D study demonstrates a pattern of diminishing clinical returns with successive pharmacological treatments. After two antidepressant failures, patients' likelihood of achieving remission with medication drops sharply, and they are considered to have treatment-resistant depression (TRD).³

Deep transcranial magnetic stimulation (Deep TMS) employs a unique mechanism of action, distinct from antidepressant drugs. In separate clinical trials with similar patient populations,[§] TRD patients achieved higher rates of remission with Deep TMS* than with either standard TMS[†] or the next-step pharmacological treatment.[‡]

There is another way – Brainsway!

Most TRD patients struggle with depression for years and many reach an impasse in their treatment. Deep TMS is FDA-cleared, effective, and has minimal side effects. The use of Brainsway's patented helmet ensures optimal and reproducible coil placement and affords comfort for both patient and operator. Deep TMS treatment is provided in daily 20-minute sessions over 4-6 weeks. Patients remain awake and alert during treatment, and are then able to resume their daily routine with no limitations.



The Deep TMS System and H1-Coil

¹ Levkovitz Y et al. World Psychiatry 2015, 14:64-73.

² Kessler RC et al. JAMA 2003, 289:3095-105.

³ Rush AJ et al. Am J Psychiatry 2006, 163:1905-17.

⁴ Fox MD et al. Neuroimage 2013, 66:151-160.

⁵ Gersner R et al. Biol Psychiatry 2010, 67:125-32.

⁶ Roth Y et al. J Clin Neurophysiol 2007, 24:31-38.

⁷ Rosenberg O et al. Depress Anxiety 2010, 27:465-9.

⁸ Ginou A et al. Brain Stimul 2014, 7:e19.

⁹ Data being prepared for submission.

[§] The Deep TMS depression treatment and standard TMS depression treatment were not compared in head-to-head studies.

* Remission rates in TRD patients with 3-4 previous failed antidepressant medication trials. From Brainsway's pivotal trial: Levkovitz Y et al. World Psychiatry (2015).


[†] Highest acute-phase remission rates reported in a DBPC trial with standard TMS. From: George MS et al. Arch Gen Psychiatry (2010).

[‡] Remission rates following step-3 pharmacological treatment in TRD patients with two previous failed antidepressant medication trials. From: STAR*D study: Rush AJ et al. Am J Psychiatry (2006).

A little difference goes a long way...

The classic figure-of-eight TMS coil provides highly focused stimulation, narrowly restricted to a few square centimeters of superficial cortical brain regions. The optimal TMS targets for depression, which are small and vary significantly between individuals,⁴ may easily be missed with this stimulation. Moreover, in a preclinical model of depression, the depth of stimulation was shown to be critical in modulating the brain's reward system and relieving depressive symptoms.⁵

Brainsway's proprietary H-Coil features a state-of-the-art design which induces an electric field in deeper and more widespread regions of the brain, achieving a 2.5-fold deeper electric field penetration at the same safe stimulation levels.⁶⁻⁸ The unique spatial characteristics of the magnetic field generated by the H-Coil may account for the improved clinical outcomes observed with Deep TMS.




Measurements in a realistic brain model demonstrate the superior depth penetration profile of Deep TMS compared to standard TMS using a figure-8 coil.

Adapted from [7].

Remission accomplished

In real-life community treatment settings, 20 sessions of Deep TMS produce remission rates even higher than those observed in clinical trials. Among patients who went on to complete a treatment course of 30 sessions, **1 in 2** achieved full remission, suggesting a definite benefit for patients completing the full 30-session treatment regimen.



Well-tolerated



Clinically proven



Endorsed by industry experts



Only TMS manufacturer with active clinical pipeline

- The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K122288.



Brainsway and the Brainsway logo are trademarks of Brainsway Ltd. For more information, scan the QR code or visit www.brainsway.com
Tel: 1.844.386.7001 | **Email:** info@brainsway.com



SLS-0001-04